Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study o…
An institutional-grade, numbers-driven thesis on REGN — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates REGN (REGN) 54/100. REGN is covered in the Unknown sector. The score blends valuation, growth, earnings quality and momentum into a single grade.
On the fundamentals, REGN shows trailing revenue of $14.34B. This page also tracks REGN's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
REGN currently carries a TradersQuant composite score of 54/100, which we read as a neutral-to-watch signal. This is research, not financial advice — always combine it with your own judgement.
TradersQuant generates a 12-month, three-scenario (bull/base/bear) model forecast for REGN. Open the live page for current figures.
TradersQuant publishes a model-based 12-month price prediction for REGN, and every call is logged and graded publicly against the S&P 500. Open the live page for current figures.
We deliberately don't publish 2030 price predictions for REGN — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
REGN does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
